Cipher Pharmaceuticals Inc. (TSE:CPH - Free Report) NASDAQ: CPHR - Analysts at Stifel Canada upped their Q4 2025 earnings per share (EPS) estimates for shares of Cipher Pharmaceuticals in a research note issued on Thursday, October 16th. Stifel Canada analyst J. Keywood now expects that the company will post earnings of $0.28 per share for the quarter, up from their prior forecast of $0.27. The consensus estimate for Cipher Pharmaceuticals' current full-year earnings is $1.29 per share.
Cipher Pharmaceuticals Stock Down 0.2%
Shares of TSE CPH opened at C$14.70 on Monday. The company has a market capitalization of C$373.29 million, a price-to-earnings ratio of 31.96 and a beta of 0.77. The company has a debt-to-equity ratio of 41.22, a current ratio of 2.00 and a quick ratio of 2.67. The business has a 50-day moving average of C$15.47 and a two-hundred day moving average of C$13.65. Cipher Pharmaceuticals has a 1 year low of C$10.61 and a 1 year high of C$17.50.
About Cipher Pharmaceuticals
(
Get Free Report)
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
